Impacting UK clinical practice: Zejula for first-line maintenance treatment of advanced ovarian cancer
Professor Jonathan Ledermann
Professor Bradley Monk
Dr Rowan Miller
Dr Shibani Nicum
Not a healthcare professional? Visit our Public site
Not a healthcare professional? Visit our Public site
has been added to your basket
59
Impacting UK clinical practice: Zejula for first-line maintenance treatment of advanced ovarian cancer
Professor Jonathan Ledermann
Professor Bradley Monk
Dr Rowan Miller
Dr Shibani Nicum
How is COVID-19 affecting the treatment and management of ovarian cancer?
Professor Jonathan Lederman
Dr Rebecca Bowen
Christina Fotopoulou
Dr Marcia Hall
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
February 2021 | PM-GB-NRP-WCNT-210002